Document is current
Any future updates will be listed below
-
Authors
Shi, Jiyun
Du, Shuaifan
Wang, Rongxi
Gao, Hannan
Luo, Qi
Hou, Guozhu
Zhou, Yidong
Zhu, Zhaohui
Wang, Fan https://orcid.org/0000-0002-4166-5776
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04267900 at ClinicalTrials.govDocuments that mention this clinical trial
Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study
https://doi.org/10.1186/s12967-022-03865-y
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (92159201, 81630045, 81927802, 81971676)
Capital Health Development Scientific Research Project (2018-1-4011)
Chinese Academy of Medical Science Clinical and Translational Medicine Research Foundation (2019XK320032)
Emergency Key Program of Guangzhou Laboratory (EKPG21-16)
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 29 December 2022
First Online: 11 January 2023
Declarations
:
: All animal experiments followed the protocol approved by the Institutional Animal Care and Use Committee at Peking University. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This study was registered at clinicaltrials.gov (NCT04267900). The use of tissues and patient information was authorized by the local ethics committee. All patients signed informed consent before their specimens and information were selected, in accordance with the rules of the ethics committee.
: All the personal data involved in this article have been signed with informed consent.
: The authors have declared that no competing interests exist.
